YSB Inc.

YSB Inc.

HHKEX:9885
3.07
HKD
-0.18
(-5.54%)
2.97BMarket Cap
Mar 15Next Earn
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
9.59
15.96
22.57
43.96
27.75
30.71
- -
Basic EPS, GAAP
-0.9
-0.79
-2.37
-8.3
0.05
0.22
- -
Free Cash Flow per Basic Share
-0.24
-0.96
0.09
1.12
0.98
0.91
- -
Dividend per Share
- -
- -
- -
- -
- -
0.07
- -
Book Value per Share
-3.89
-4.59
-6.88
3
3.43
3.6
3.45
Tangible Book Value per Share
-4.01
-4.78
-7.05
2.85
2.25
2.48
2.39
Basic Weighted Avg Shares
632
632
632
386
645
683
674
Sales/Revenue/Turnover
6,065
10,094
14,275
16,972
17,904
20,970
- -
Operating Margin (%)
-4.9
-3.98
-1.65
-0.29
-0.47
0.33
- -
Depreciation Expense
82
102
135
134
129
153
- -
Net Income, GAAP
-572
-502
-1,500
-3,207
30
153
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-9.43
-4.97
-10.51
-18.89
0.17
0.73
- -
Working Capital
-3,155
-3,653
-4,691
1,627
1,296
1,097
647
LT Debt
105
118
99
90
130
96
90
Total Equity
-2,462
-2,908
-4,370
1,884
2,269
2,386
2,331
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
1.42
6.42
- -

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
176
232
207
LT Borrowings
- -
- -
- -
LT Finance Leases
107
96
90
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
676
679
690
Market Capitalization
5,858
3,278
2,573

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
5,222
6,001
5,516
Cash, Cash Equivalents & STI
1,952
1,745
1,757
Accounts Receivable, Net
82
94
93
Inventories
1,661
1,873
1,912
Total Current Liabilities
4,213
4,904
4,869
Payables & Accruals
- -
- -
- -
ST Debt
176
232
207
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-9.82%
5.18%
Free Cash Flow
- -
187.21%
-2.05%
Net Income, GAAP
- -
121.85%
409.66%
Sales/Revenue/Turnover
- -
29.88%
17.13%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
17,904
2025
- -
- -
20,970
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.05
2025
- -
- -
0.22
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.07
2026
- -
- -
- -

Company Description

CEO
Bu Zhen Zhang
Full Time Employees
6,950
Sector
Technology services
Industry
Packaged software
Address
Yaoshibang Building Guangzhou GD China
IPO Date
Jun 28, 2023
Website
ysbang.cn
Business
YSB Inc. (9885.HK) is a Cayman Islands-incorporated investment holding company primarily engaged in providing digital pharmaceutical platforms, wholesale and retail of pharmaceuticals and healthcare products, and related SaaS solutions for pharmaceutical companies, distributors, vendors, pharmacies, and primary healthcare institutions in China. The company offers ClouMinihouse, a primary smart healthcare system comprising Future Lou point-of-care testing and monitoring devices, Cloud consultation SaaS for digital clinic management, and ClouWiseDoctor AI doctors-aid system; wePharmacy smart unmanned pharmaceutical booths with maintenance services; ClouDiagnos diagnostic testing; YSB eLearn online pharmacist qualification courses; drugstore SaaS including palm store easy versions, Galaxy+ procurement, Xentrum warehousing, IntelNex delivery, and real-sales settlement tools; wholesaler ERP, WMS logistics, and financial systems; as well as clinic and manufacturer SaaS for marketing, promotion, and supply chain services through a nationwide network of 22 strategic warehouses covering over 2,000 counties, 49,100 drugstores, 35,300 grassroots institutions, and 15,000 merchants. Founded in 2015 and headquartered in Yaoshibang Building, TIT Creative Industry Zone, Guangzhou, China, YSB operates principally in the domestic market with 6,763 employees and focuses on outside-hospital pharmaceutical circulation, medical testing, and self-operated businesses that grew 12.5% in the first half of 2025. In late 2024, the company completed the RMB1.035 billion acquisition of 100% equity in Yikuai Pharmaceutical (also referred to as Folding Space Cayman or CSI Healthcare), with RMB420 million cash and RMB615 million in shares issued at HK$12 each including 31.7 million shares on November 26, 2024, to accelerate its proprietary brand expansion; additionally, executives such as CFO Fei Chen increased holdings by 1.3 million shares since April 2025, signaling confidence amid a 258% H1 2025 profit surge.